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Background: Diabetic patients have a significantly worse prognosis after an acute myocardial infarction (AMI) than
their counterparts. Previous studies have shown that the number of circulating endothelial progenitor cells (EPCs)
significantly increase early after an AMI in normoglycemic patients. However, it is well known that type 2 diabetes
mellitus (DM) is associated with impaired function and reduced circulating EPCs levels. Nonetheless, few studies
have analyzed EPCs response of diabetics to an AMI and the EPC response of pre-diabetic patients has not been
reported yet. Therefore, we hypothesized that in the acute phase of an AMI, diabetic and pre-diabetics have lower
circulating EPCs levels than patients with normal glucose metabolism. We also evaluated the possible capacity of
chronic antidiabetic treatment in the recovery of EPCs response to an AMI in diabetics.
Methods: One-hundred AMI patients were prospectively enrolled in the study. Using the high-performance flow
cytometer FACSCanto II, circulating EPCs (CD45dimCD34+KDR+ and CD45dimCD133+KDR+ cells) were quantified,
within the first 24 hours of admission. In addition, as an indirect functional parameter, we also analyzed the fraction
of EPCs coexpressing the homing marker CXCR4.
Results: We found that in the acute phase of an AMI, diabetic patients presented significantly lower levels of
circulating CD45dimCD34+KDR+ and CD45dimCD133+KDR+ EPCs by comparison with nondiabetics, with a parallel
decrease in the subpopulations CXCR4+ (p < 0.001). Indeed, this study suggests that the impaired response of EPCs
to an AMI is an early event in the natural history of DM, being present even in pre-diabetes. Our results, also
demonstrated that numbers of all EPCs populations were inversely correlated with HbA1c (r = −0.432, p < 0.001
for CD45dimCD34+KDR+ cells). Finally, this study suggests that previous chronic insulin therapy (but not oral
antidiabetic drugs) attenuate the deficient response of diabetic EPCs to an AMI.
Conclusion: This study indicates that there is a progressive decrease in EPCs levels, from pre-diabetes to DM, in
AMI patients. Moreover, glycemic control seems to be determinant for circulating EPCs levels presented in the acute
phase of an AMI and chronic insulin therapy may probably attenuate the deficit in EPCs pool seen in diabetics.
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It is well recognized that patients with type 2 diabetes mel-
litus (DM) have accelerated atherosclerosis, increased risk
of developing coronary artery disease (CAD) and worse
prognosis after an acute myocardial infarction (AMI) [1].
Endothelial progenitor cells (EPCs), a subpopulation of
adult stem cells, have emerged as critical to endothelial
repair and vascular homeostasis. Although the mecha-
nisms whereby EPCs protect the cardiovascular system
are still not fully understood, it has been extensively
demonstrated that these bone marrow-derived cells
contribute to endothelial repair and postnatal neovascu-
larization [2,3]. EPCs can differentiate into mature endo-
thelial cells and be incorporated into new vessels or act
by a paracrine manner, through the secretion of pro-
angiogenic growth factors that enhance vascularization
mediated by resident endothelial cells and/or promote
angiogenesis [2-5].
The number of EPCs in peripheral circulation is gener-
ally low, and in normal physiological conditions, these
endothelial precursor cells are very rare in blood, but
they are mobilized from the bone marrow to the periph-
eral circulation in response to tissue injury, such as
myocardial ischemia [6]. In fact, tissue ischemia is con-
sidered the strongest stimulus for EPCs mobilization
and it has been shown that their numbers significantly
increase in patients with an AMI [7,8]. However, it is
well established that diabetic patients present impaired
function and reduced numbers of circulating EPCs,
reflecting a poor endogenous regenerative capacity that
may contribute to the development of vascular compli-
cations and to the dismal prognosis associated with this
prevalent disease [9-12]. Therefore, it is likely that, in
the clinical context of myocardial infarction, diabetic pa-
tients also have lower levels of circulating EPCs, but
regrettably the data addressing the dynamics of EPCs
mobilization in diabetic patients with AMI are scarce.
Furthermore, little is known about potential EPCs im-
pairment in pre-diabetic states and no studies are avail-
able on the kinetics of EPCs mobilization in pre-diabetic
patients with AMI. This is of great importance, since
multiple studies have demonstrated that individuals with
pre-diabetes are also at increased risk for cardiovascular
events [13]. On the other hand, some drugs commonly
prescribed in diabetic patients, like statins, angiotensin
II receptor blockers (ARBs) and angiotensin-converting-
enzyme (ACE)-inhibitors, have been shown to increase
the number of EPCs in peripheral blood of patients with
stable CAD [14]. However, we have no data available re-
garding the impact of previous antidiabetic treatment on
EPC response to an AMI, in diabetic patients.
In this study, we tested the hypothesis that diabetes
and pre-diabetes states were associated with reduced cir-
culating EPCs levels in the acute phase of a myocardialinfarction (MI) by comparison with patients with normal
glucose metabolism. We also examined the impact of
previous antidiabetic treatment on the dynamics of EPCs
mobilization in diabetic patients following an AMI.
Methods
Study population and selection
A prospective cohort of 686 consecutive patients hospi-
talized in a single Coronary Care Unit (CCU) due
to myocardial infarction, from 5 January 2009 to 23
September 2011, were screened on admission for inclu-
sion. Screening included an interview, clinical examin-
ation, ECG and laboratory assessment. Patients were
excluded if they were >80 years old, showed clinical or
biochemical evidence of concomitant inflammatory dis-
ease, known auto-immune or malignant diseases, severe
peripheral arterial occlusive disease, deep vein throm-
bosis or pulmonary embolism, atrial fibrillation, recent
trauma or surgery (<1 month), recent major bleeding re-
quiring blood transfusion (<6 months), renal insuffi-
ciency (creatinine > 2.0 mg/dl), anemia (hemoglobin <
8.5 g/dl) or thrombocytopenia (<100 000/L), previous cor-
onary bypass surgery, myocardial infarction within the pre-
ceding 2 months, cardiogenic shock, severe valvular disease
or congenital heart disease, co-morbidities associated with a
life expectancy less than 2 years. A regular use of nonsteroi-
dal anti-inflammatory drugs or anticoagulants, patients with
pacemakers, implantable cardioverter defibrillators or
resynchronization devices, and excessive alcohol consump-
tion or illicit drugs abuse that may influence EPC kinetics
were also exclusion criteria. A total of 100 patients were
prospectively included (65% with ST segment elevation
myocardial infarction – STEMI and 35% with non-ST seg-
ment elevation myocardial infarction - NSTEMI) (Figure 1).
All patients received the standard therapy for the acute
phase of MI that included acetylsalicylic acid (ASA), clo-
pidogrel and low-molecular-weight heparin, according to
usual hospital practice.
Baseline demographic data, cardiovascular risk factors
and previous medications were recorded in all patients.
Smoking status was recorded as ever-smoker (past or
current) or non-smoker.
Blood samples were collected to assess chemistry
(including fasting plasma glucose (FPG) and glycosylated
hemoglobin (HbA1C)), total cholesterol, low-density
lipoprotein-cholesterol (LDL-C), high-density lipopro-
tein-cholesterol (HDL-C), triglycerides, high sensitivity
C-reactive protein (hs-CRP), creatinine, and hematolo-
gical parameters in all patients according to standard
hospital practice.
The study was approved by the local ethics committee
(Approval Number: HUC-23-08). All patients gave written
informed consent and research was conducted according
to the principles expressed in the Declaration of Helsinki.
Figure 1 Flow diagram of patient recruitment. AF, atrial fibrillation; AMI, acute myocardial infarction; CABG, coronary artery bypass graft;
Hb, hemoglobin; MI, myocardial infarction; yrs, years old.
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DM and glucose metabolism disorders were defined ac-
cording to the American Diabetes Association (ADA)
criteria [15,16]. All patients without previously known
diabetes underwent an Oral Glucose Tolerance Test
(OGTT) on day 4 or 5 of hospitalization. Therefore,
patients were classified as having diabetes if they have a
FPG ≥126 mg/dl, a 2-h glucose ≥200 mg/dl on OGTT, a
A1c ≥ 6.5% or a random plasma glucose ≥200 mg/dl in
a patient with classic symptoms of hyperglycemia or
hyperglycemic crisis. For patients without diabetes, pre-
diabetes was defined as FPG levels of 100–125 mg/dl(impaired fasting glucose – IFG), 2-hour OGTT glucose
level of 140–199 mg/dl (impaired glucose tolerance -
IGT) or HbA1c values of 5.7%-6.4%. Patients were clas-
sified as having a normal glucose metabolism (NGM)
if they have FPG < 100 mg/dl, 2-hour OGTT glucose
level < 140 mg/dl and HbA1c <5.7%.
Quantification of circulating EPCs by flow cytometry
For the identification and quantification of EPCs, we
have used a standardized protocol - the modified Inter-
national Society for Hematotherapy and Graft Engineer-
ing (ISHAGE) sequential gating strategy - proposed by
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CCU admission, 1 ml of whole blood was collected from
a forearm vein into EDTA tubes, transported into the
cytometry laboratory and processed within 1 to 2 hours
of collection. Hence, 150 μl of whole blood were incu-
bated with the following combination of anti-human
monoclonal antibodies: 10 μl of anti-CD133 conjugated
with allophycocyanin (APC) (Miltenyi Biotec), 5 μl of
anti-CD45 conjugated with APC-H7 (Becton Dickinson),
10 μl of anti-KDR (also known as type 2 vascular endo-
thelial growth factor receptor - VEGF-R2) conjugated
with phycoerythrin (PE) (Sigma), 10 μl of anti-CD34
conjugated with fluorescein isothiocyanate (FITC) (Becton
Dickinson) and 10 μl of anti-CD184 (also known as
CXCR4) conjugated with PE-Cyanine 5 (PE-Cy5) (BD
Pharmingen) for 30 min at 4°C, in the dark. Red blood
cell lysis was performed using FACS Lysing Solution
(BDBiosciences) diluted 1:10 (vol/vol) in distilled water
and washed with phosphate-buffered-saline (PBS) before
flow cytometry acquisition. Data acquisition was per-
formed with a high-performance flow cytometer, a
BDBioscience FACSCanto II, which can analyze with
high resolution up to eight different fluorescent markers
from a large number of events and we used the flow
cytometry software Infinicyt 1.5 (Cytognos) for the
analysis. According to the used standardized protocol,
human circulating EPCs were identified by a minimal
antigenic profile that includes at least one marker of
stemness/immaturity (CD34 and/or CD133), plus at
least one marker of endothelial commitment (KDR).
CD45 staining was also performed to exclude leucocytes,
as it has been previously demonstrated that only the
fraction of CD45dim cells harbours the “true” circulating
EPCs [18]. CXCR4, the receptor for stromal cell–derived
factor-1 (SDF-1), is a cell surface antigen expressed in
EPCs, which plays a key role in their transendothelial
migration and homing to sites of vascular injury [19].
Therefore, by analyzing the subpopulation of progenitors
coexpressing CXCR4, we could study a functional param-
eter of EPCs. As isotype controls are known to mask rare
cell populations, none were used in this analysis, and base-
line fluorescence was determined using unstained cells
[20]. Because EPCs are extremely rare events in peripheral
blood, additional strategies were applied in order to in-
crease the sensitivity of the method and the accuracy of
our work. These included: automatic compensation for
minimizing fluorescence spillover, exclusion of dead cells,
and use of specific high quality mononuclear antibodies.
The total number of acquired events was increased to at
least 1 million per sample, which is generally not needed
for most other applications of flow cytometry. Circulating
EPCs were measured in triplicate from the same patients,
revealing a very close correlation (r = 0.87, p < 0.0001).
The same trained operator, who was blind to the clinicalstatus of the patients, performed all the cytometric ana-
lysis throughout the study.
Four different populations of EPCs were quantified: 1)
CD45dimCD133+KDR+ cells; 2) CD45dimCD34+KDR+
cells; 3) CD45dimCD34+CD133+KDR+ triple positive
cells; and 4) the subpopulation of CD45dimCD34+KD
R+CXCR4+ EPCs.Patients follow up for cardiovascular events
All patients were followed up for 24 months after dis-
charge. The following cardiovascular events were recorded:
cardiovascular death; nonfatal stroke or transient ischemic
attack; re-infarction; unstable angina and re-hospitaliza-
tion for unstable angina or heart failure. We also analyzed
the combined endpoint of cardiovascular death, re-hospi-
talization for ACS and unplanned PCI – Major Adverse
Cardiac Events (MACE). Cardiovascular death was de-
fined as death due to a MI or stroke or documented
sudden cardiac death. For patients experiencing more
than one acute event, only the first event was consid-
ered in the analysis.Statistical analysis
Statistical analyses were performed using SPSS software
version 20.
Based on previous data, we estimated a 40% reduction
in circulating EPCs of diabetics by comparison with non-
diabetic patients. Therefore, a minimum sample size of
18 patients in each group would provide 90% power to
detect difference in circulating EPCs between diabetic
and nondiabetic patients, using a two-sided hypothesis
test with a significance level (alpha) of 0.05.
Continuous variables were tested for normal distribution
by Kolmogorov–Smirnov test and expressed as mean ±
standard deviation or median ± interquartile range for
parametric and nonparametric data, respectively. Categor-
ical data are expressed as counts and percentages.
For comparison of continuous data unpaired Student
t-tests or ANOVA tests were used when variables were
normally distributed and nonparametric Mann–Whitney
test or Kruskal-Wallis test for variables without a normal
distribution. Categorical variables were compared with
the chi-square test or with Fisher exact test as appropriate.
The relationship between variables was calculated using
Pearson’s or Spearman’s correlation coefficient, whichever
appropriate. Multivariate linear regression analysis was
used to assess the relationship between circulating EPCs
levels and HbA1c, after adjustment for confounding var-
iables. Kaplan-Meier survival analyses were performed
to evaluate time-dependent outcomes. Differences between
pairs of survival curves were tested by the log-rank test.
For all analyses, a 2-sided value of P < 0.05 was considered
statistically significant.
Table 1 Comparison of clinical characteristics between diabetic and nondiabetic patients
Non-diabetics (N = 62) Type 2 diabetics (N = 38) p value
Age (years)* 59.8 ± 10.3 61.5 ± 11.0 0.300
Male gender (%) 90.3 89.5 0.891
BMI (Kg/m2)* 27.9 ± 4.4 29.2 ± 6.9 0.251
Previous CAD (%) 14.5 31.6 0.075
Previous MI (%) 11.3 18.4 0.319
Type of MI
STEMI vs NSTEMI (%) 66.1/33.9 63.2/36.8 0.762
Cardiovascular risk factors
Hypertension (%) 56.5 84.2 0.004
Smoking habits (%) 61.3 47.4 0.215
Family history (%) 37.1 28.9 0.492
Hyperlipidemia (%) 71.1 82.3 0.189
Physical inactivity (%) 56.5 60.5 0.689
Previous cardiovascular or antidiabetic drugs
Statins (%) 29.0 31.6 0.825
ASA (%) 19.4 42.1 0.021
ACEI (%) 12.9 36.8 0.007
ARB (%) 12.9 31.6 0.038
Beta-blockers (%) 9.7 21.1 0.141
Insulin (%) 0.0 26.3 <0.001
Oral hypoglycemic (%) 0.0 65.8 <0.001
Baseline laboratory
Admission Troponin I (μg/L)§ 0.7 ± 5.8 1.5 ± 3.6 0.798
Peak Troponin I (μg/L)§ 55.4 ± 71.6 56.7 ± 64.7 0.793
HbA1C (%)§ 5.6 ± 0.5 7.1 ± 2.2 <0.001
Admission glycemia (mg/dl)§ 109.0 ± 31.0 206.5 ± 110.8 <0.001
First fasting glycemia (mg/dl)§ 103.0 ± 24.5 156.0 ± 52.5 <0.001
Total cholesterol (mg/dl)* 178.5 ± 59.0 211.7 ± 54.9 0.007
LDL cholesterol (mg/dl)* 113.2 ± 39.6 145.3 ± 44.3 <0.001
HDL cholesterol (mg/dl)§ 40.2 ± 9.5 38.7 ± 12.9 0.164
Triglycerides (mg/dl)§ 138.5 ± 109.5 148.0 ± 88.5 0.801
Uric acid (mg/dl)* 5.6 ± 1.3 6.2 ± 1.4 0.096
Baseline creatinine (mg/dl)§ 0.8 ± 0.3 0.9 ± 0.4 0.123
Baseline hemoglobin (g/dl)* 14.8 ± 1.4 14.4 ± 1.2 0.200
Admission hs-CRP (mg/dl)* 0.9 ± 1.3 1.0 ± 1.4 0.872
LVEF (%)* 52.6 ± 9.6 50.0 ± 11.8 0.104
Hospital length of stay§ 5.4 ± 2.6 5.9 ± 3.0 0.424
ACEI, Angiotensin-Converting Enzyme Inhibitors; ARB, Angiotensin II receptor blockers; ASA, acetylsalicylic acid; CAD, coronary artery disease; hs-CRP, high
sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation
myocardial infarction.
*mean ± SD.
§median ± interquartile range.
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Characteristics of the study population
There were 38 patients with DM, 13% of them with newly
diagnosed DM. Overall, diabetics had similar age andcardiovascular risk factors as nondiabetic patients, except
for hypertension that was significantly more frequent in
diabetics (Table 1). Additionally, they tended to have more
frequently previously known CAD and were more often
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oral hypoglycemic agents and insulin before admission
than nondiabetics. As expected, diabetics had significantly
higher levels of admission glycemia, fasting glycemia and
HbA1c and also presented higher total cholesterol and
LDL-cholesterol than nondiabetics.
There were no significant differences in MI presentation
(STEMI versus NSTEMI), left ventricular function or
renal function between groups (Table 1).
There were no significant differences in the extent of
coronary atherosclerosis, number of stents deployed or
other cath lab parameters between diabetics and nondia-
betics (Table 2).
Reduction of circulating EPCs in diabetic patients
Circulating EPCs levels were expressed for one million
cytometric events (Figure 2). Diabetic patients had circu-
lating numbers of CD45dimCD34+KDR+ cells reduced
by 63% when compared with nondiabetics, with a paral-
lel decrease in the subpopulation CXCR4+ (Table 3,
Figure 3). There was also a significant reduction in
the more immature population of CD45dimCD34+CD
133+KDR+ EPCs to around half the levels of nondia-
betics, and numbers of its precursors CD45dimCD13
3+KDR+ in peripheral circulation were also significantly
decreased. The subpopulation coexpressing the homing
marker CXCR4 (CD45dimCD133+KDR+CXCR4+) was
also significantly reduced in diabetics (Table 3).
Circulating EPCs levels across the different disorders of
glucose metabolism
Upon OGTT, 24 of the nondiabetic patients had pre-
diabetes (29.2% with impaired fasting glucose - IFG,
58.3% with impaired glucose tolerance – IGT and 12.5%
with both disorders of glucose metabolism).
Circulating CD45dimCD34+KDR+ EPCs decreased as
a continuum from NGM to DM, as there was aTable 2 Comparison of catheterization lab data between diab
Non-diab





Left main disease (%)
LAD disease (%)
PCI before EPCs evaluation (%)
Complete revascularization before EPCs evaluation (%)
Number of stents deployed before EPCs evaluation 1.6
LAD; left anterior descending, PCI; percutaneous coronary intervention.reduction of approximately 40% in patients with pre-
diabetes as compared with NGM patients (p = 0.018)
and there was an additional reduction of these EPCs of
about 40% (p = 0.042) when diabetics were compared with
patients with pre-diabetes (Table 4). Nonetheless, the popu-
lation of more immature progenitor cells (CD45dimCD133
+KDR+) and the subpopulations coexpressing the CXCR4
marker (CD45dimCD34+KDR+CXCR4+ and CD45dimCD
133+KDR+CXCR4+) were not significantly reduced in pre-
diabetic patients by comparison with NGM patients (5.4 ±
2.4 vs 3.9 ± 2.8, p = 0.314; 1.8 ± 0.9 vs 1.3 ± 1.2, p = 0.175;
and 3.5 ± 2.1 vs 3.2 ± 1.3, p = 0.290, respectively), whereas a
significant reduction was apparent from pre-diabetic to
diabetic patients on these cells levels (p = 0.022; p = 0.045
and p = 0.015, respectively) (Table 4).Circulating EPCs numbers according to previous
antidiabetic treatment
Regarding the antidiabetic strategy before admission,
there were 53% of diabetic patients on oral hypoglycemic
drugs, 26% insulin-treated diabetics, and 21% of patients
who were not taking any antidiabetic drug (because they
were on diet-only therapy or new onset DM was diag-
nosed during hospitalization). As expected, diabetes dur-
ation was significantly longer in insulin-treated patients
(13.5 ± 9.8 years versus 6.8 ± 5.0 in patients on oral
hypoglycemic drugs versus 1.7 ± 1.2 in diabetics not re-
ceiving any antidiabetic drug, p = 0.001). Insulin-treated
DM (ITDM) patients and diabetics not previously treated
with antidiabetic drugs presented a worse glycemic control
as compared with patients on oral hypoglycemic drugs
(Figure 4).
Numbers of CD45dimCD34+KDR+ EPCs were signifi-
cantly reduced in diabetic patients previously treated
with oral antidiabetic drugs and in diabetics not taking
any hypoglycemic drug when compared with nondia-
betic patients (Figure 5, A). However, despite the worseetics and nondiabetics










± 1.1 1.8 ± 1.2 0.649
Figure 2 Representative flow cytometry quantification of CD45low/CD34+/KDR+ EPCs in a a nondiabetic patient with STEMI. (A) The
cluster of CD34+ cells (red points) was analyzed using FITC-labeled antibodies against CD34 vs. SSC. B) CD45dim subset analysis was conducted
using APC-H7-labeled antibodies against CD45 vs SSC. At this step, events forming a cluster of characteristic low SSC and low CD45 fluorescence
(SSClowCD45dim cells) expressed CD34+CD45dim cells (light blue events). C) The events fulfilling previous criteria were then displayed on a
forward light scatter (FSC) vs. SSC dot plot to confirm that the selected cells fall into the lymphocyte region. D) Finally, CD45dimCD34+KDR+
endothelial progenitor cells (pink cells) are deducted in the dot plot of PE-labeled antibodies against KDR vs CD34.
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CD45dimCD34+KDR+ EPCs levels were not signifi-
cantly reduced compared to that of nondiabetic patients
(p = 0.160) (Figure 5-A). Regarding the subpopulation
of CD45dimCD34+KDR+ cells also expressing the hom-
ing marker CXCR4+, all diabetes treatment categories
presented significantly decreased circulating levels bycomparison with nondiabetic patients (Figure 5-B). Cir-
culating CD45dimCD133+KDR+ cell levels showed a
progressive decline from nondiabetics, untreated DM,
DM on oral hypoglycemic drugs and finally, ITDM, with
patients receiving insulin and patients on oral hypo-
glycemic drugs presenting significantly lower levels
as compared with nondiabetics (p = 0.002 and p = 0.004,
Table 3 Comparison of circulating EPCs levels between diabetics and nondiabetics
Non-diabetics (n = 62) Type 2 diabetics (n = 38) p value
Time from PCI to blood sampling (hours) 13.8 ± 14.7 11.6 ± 11.7 0.649
CD34+ cells/106 WBC 228.8 ± 136.7 197.0 ± 115.2 0.098
CD133+/106 WBC 54.4 ± 35.7 36.0 ± 18.0 0.020
CD45dimCD34+KDR+ cells/106 WBC 6.2 ± 3.0 2.3 ± 0.9 <0.001
CD45dimCD34+KDR+CXCR4+ cells/106 WBC 1.8 ± 1.1 0.8 ± 0.7 <0.001
CD45dimCD34+CD133+KDR+ cells/106 WBC 2.1 ± 1.1 1.0 ± 0.8 <0.001
CD133+KDR+/106 WBC 4.6 ± 2.9 3.1 ± 1.6 <0.001
CD133+KDR+CXCR4+/106 WBC 3.5 ± 1.9 2.0 ± 1.2 <0.001
PCI, percutaneous coronary intervention; WBC, white blood cells.
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5dimCD133+KDR+CXCR4+ subpopulation were also
significantly lower in all diabetic treatment categories
than in nondiabetic patients (Figure 5-D).
Impact of glycemic control on EPCs levels
There were significant negative correlations between
levels of circulating CD45dimCD34+KDR+ (Figure 6, A),
CD45dimCD133+KDR+ progenitors (Figure 6, C), their
CXCR4+ subpopulations (Figure 6, B and D) and HbA1c.
CD45dimCD34+KDR+EPCs and their subpopulation CD45
dimCD34+KDR+CXCR4+ were also inversely correlated with
fasting glycemia (r = − 0.371, p < 0.001 and r = − 0.213,
p = 0.046, respectively). Nonetheless, EPCs levels wereFigure 3 Comparison of circulating EPCs levels between diabetics and
range of circulating EPCs numbers quantified by flow cytometry. Mann Wh
nondiabetic EPCs levels.not correlated with DM duration. Levels of circulating
CD45dimCD34+KDR+ and CD45dimCD133+KDR+ pro-
genitors were also negatively correlated with age (r =− 0.285,
p = 0.007 and r =− 0.343, p = 0.001, respectively).
Remarkably, correlations with HbA1c remain signifi-
cant even after adjustment for age, gender, hypertension,
LDL-cholesterol, family history of CAD, smoking habits
and physical inactivity (Table 5).
Prognostic impact of EPCs
Clinical outcomes during the 24 months follow-up
period are represented in Table 6.
There were no significant differences in re-infarction,
nonfatal stroke/transient ischemic attack or cardiovascularnondiabetics. Bars represent median and error bars interquartile
itney U test was used for the comparison between diabetic and
Table 4 Comparison of circulating EPCs levels between the different glucose metabolism status
NGM (n = 38) Pre-diabetes (n = 24) Diabetes (n = 38) p value
CD34+ cells/106 WBC 417.3 ± 266.9 225.4 ± 97.5 176.5 ± 148.8 0.006
CD133+/106 WBC 41.5 ± 23.7 34.1 ± 21.2 34.4 ± 19.2 0.101
CD45dimCD34+KDR+ cells/106 WBC 7.0 ± 3.5 4.3 ± 2.7 2.4 ± 1.2 <0.001
CD45dimCD34+KDR+CXCR4+ cells/106 WBC 1.8 ± 0.9 1.3 ± 1.2 0.8 ± 0.7 0.002
CD45dimCD34+CD133+KDR+ cells/106 WBC 1.7 ± 1.0 1.3 ± 1.1 0.7 ± 0.6 0.001
CD133+KDR+/106 WBC 5.4 ± 2.4 3.9 ± 2.8 3.0 ± 1.9 0.002
CD133+KDR+CXCR4+/106 WBC 3.5 ± 2.1 3.2 ± 1.3 2.0 ± 1.4 0.002
NGM, normal glucose metabolism; WBC, white blood cells.
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of unstable angina, the composite endpoints MACE and
re-hospitalization for unstable angina or heart failure were
significantly higher in diabetics, with the following odds
ratios 6.89 (95% CI, 1.35-35.19), 4.23 (95% CI 1.43-12.53)
and 4.82 (95% CI 1.52-15.30), respectively.
Regarding baseline circulating EPCs levels, patients with
unstable angina, unplanned PCI or MACE during follow-
up presented significantly lower levels of CD45dimCD3
4+KDR+ and CD45dimCD133+KDR+ EPCs. Levels of
the CD45dimCD133+KDR+CXCR4+ EPCs subpopulation
were also significantly reduced, at baseline, in patients
who underwent unstable angina or MACE during the
2-year follow-up period (Figure 7). Additionally, the
Kaplan–Meier survival curves for freedom from MACEFigure 4 Glycosylated hemoglobin levels according to chronic antidia
the horizontal lines show the median, and whiskers represent the maximum
treatment categories there were significant differences, we compared twoaccording to EPCs levels showed a significantly lower
event-free survival rate in patients with lower EPCs levels
in the early phases of AMI (log-rank test, p = 0.023 for
CD45dimCD34+KDR+ EPCs and log-rank test, p = 0.004
for CD45dimCD133+KDR+ cells) (Figure 8).
Discussion
There were four major findings in the present study. First,
we confirmed that, in the acute phase of a MI, diabetic pa-
tients present dramatically reduced levels of circulating
EPCs by comparison with nondiabetics. Second, this study
showed for the first time that even pre-diabetes reduces
EPCs response to an AMI, since EPCs levels were signifi-
cantly reduced in pre-diabetics and further reduced in
diabetics as compared with patients with NGM. Third,betic treatment. Box plots represent the interquartile range of values,
and minimum values. In order to find between which antiadiabetic
by two groups using the Mann Whitney U test.
Figure 5 Comparison of circulating EPCs levels between nondiabetic patients and diabetics under different antidiabetic treatments.
(A) Circulating numbers of CD45dimCD34+KDR+ cells; (B) Circulating numbers of CD45dimCD34+KDR+CXCR4+ cells; (C) Circulating numbers of
CD45dimCD133+KDR+ cells and (D) Circulating numbers of CD45dimCD133+KDR+CXCR4+ cells. Bars represent median and error bars interquartile
range of circulating EPCs numbers quantified by flow cytometry. We compared two by two groups using the Mann Whitney U test, to evaluate
between which antiadiabetic treatment category there were significant differences.
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http://www.cardiab.com/content/13/1/101previous chronic insulin therapy (but not oral antidiabetic
drugs) seems to attenuate the deficit in circulating EPCs
seen in diabetic patients with an AMI. Finally, we have
demonstrated that the degree of glycemic control is an im-
portant determinant of circulating EPCs numbers in the
setting of an AMI.
An AMI is a recognized pathological stimulus for
EPCs mobilization. In fact, patients with AMI present
significantly increased numbers of circulating EPCs as
compared with control subjects or with patients with
stable angina [8]. It has been shown that circulating
EPCs increase immediately after the onset of an AMI,
with a subsequent peak at day 5 and a rapid decline
thereafter, normalizing within 2 months [21,22]. Circu-
lating EPCs constitute a key endogenous repair mechan-
ism to counteract ongoing endothelial cell injury, replace
dysfunctional endothelium, and enhance tissue repair after
ischemic vascular injury [23]. Of note, depletion ofcirculating EPCs pool and impaired migratory activity of
these progenitor cells have been shown to be predictive of
future adverse cardiovascular events [24,25]. In accord-
ance with these previous studies, our work showed that
freedom from MACE following an AMI was significantly
poorer in patients with lower baseline EPCs levels.
It has been extensively demonstrated that patients
with DM have a profound reduction of EPCs levels in
peripheral blood, which has been correlated with the
high cardiovascular morbidity and mortality associated
with diabetes [10,26]. Additionally, reduced EPCs num-
bers have been independently associated with impaired
myocardial function in diabetic patients [27]. Fadini
et al. have demonstrated in diabetic animals, a deficient
EPCs mobilization and impaired compensatory angio-
genesis after hindlimb ischaemia-reperfusion injury [28].
However, in the clinical setting of AMI, and despite the
important vascular protective role of EPCs, to date, only
Figure 6 Relationship between levels of circulating EPCs and HbA1c. Scatter plots showing significant negative relationship relationship
(Pearson correlation) between HbA1c and circulating levels of: A) CD45dimCD34+KDR+ cells; B) CD45dimCD34+KDR+CXCR4+ cells; C) CD133+KDR+
cells; D) CD133+KDR+CXCR4+ cells.
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http://www.cardiab.com/content/13/1/101three clinical studies have studied the dynamics of EPCs
mobilization in diabetic patients [21,22,29]. In those
studies, circulating EPCs levels were decreased in dia-
betics [21,22] (or hyperglycemic patients, in the Marfella
et al. study) [29] compared with non-diabetic patients
immediately after the onset of AMI (day 1). Moreover, it
has been demonstrated that the peak level of circulating
EPCs was delayed in diabetic patients compared with
that of nondiabetic patients (from day 5 in nondiabetic
patients to day 7 in diabetic patients) [21,22]. Consistent
with these previous studies, the present work confirmed
that circulating EPCs levels were strikingly reduced in the
early phases of an AMI in diabetic patients as compared
with nondiabetic patients. Of note, this importantly reduc-
tion in EPCs levels seen in diabetic patients does not seem
justified by differences in myocardial ischemia or different
coronary revascularization procedures between groups, asvalues of troponin I (a highly specific marker of myocar-
dial injury) and coronary revascularization were similar in
diabetic and nondiabetic patients.
It has become evident that circulating EPCs numbers
were inversely correlated to the severity of CAD [30,31].
However, in the present study the huge difference in
EPCs levels between AMI diabetics and nondiabetics
cannot be explained by differences in CAD severity,
since there were no significant differences in the exten-
sion of coronary stenosis between both groups.
A large body of evidence links classical cardiovascular
risk factors, such as hypertension, with reduction in cir-
culating EPCs [32]. In this study population, diabetics
presented a significantly higher prevalence of hypertension
that could exacerbate the difference in EPCs levels as
compared with nondiabetics. However, diabetics were also
more frequently treated with drugs that recognizably
Table 5 Multivariate regression analysis assessing the correlation between HbA1c and circulating progenitor cells
levels, after adjustment for other cardiovascular risk factors than diabetes










HbA1c −0.308 0.019 −0.260 0.031 −0.342 0.009 −0.416 0.001
Age −0.188 0.217 −0.107 0.482 −0.254 0.090 −0.052 0.720
Gender 0.208 0.067 0.207 0.119 0.044 0.740 0.158 0.233
Hypertension −0.071 0.597 −0.075 0.579 0.025 0.855 −0.015 0.905
LDL-cholesterol −0.057 0.683 −0.047 0.727 −0.176 0.202 −0.148 0.267
Family history of CAD −0.129 0.361 −0.170 0.202 0.081 0.560 0.078 0.563
Smoking habits 0.003 0.985 −0.204 0.188 −0.086 0.563 −0.133 0.369
Physical inactivity −0.203 0.139 −0.080 0.556 −0.057 0.657 −0.167 0.180
Adjusted R2 0.264 … 0.256 … 0.246 … 0.247 …
Significance (ANOVA) … 0.032 … 0.040 … 0.046 … 0.033
CAD, coronary artery disease; HbA1c, hemoglobin A1c; LDL, low density lipoprotein.
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http://www.cardiab.com/content/13/1/101increase circulating EPCs numbers, such as ACE-
inhibitors and ARBs, what would counterbalance the
possible reduction on EPCs numbers due to the higher
prevalence of hypertension [14].
EPCs can be identified on the basis of the expression
of surface markers, by flow cytometry, a method consid-
ered the gold standard for the quantification of these
cells in peripheral blood [33]. Of note, there are no
unique or specific surface antigen that can be used to
identify circulating EPCs. Therefore, FACS protocols
must use the combination of various membrane markers
for EPCs quantification. In the present work, we used a
standardized polychromatic FACS protocol based upon
the detection of CD34 (an adhesion molecule expressed
mainly on haematopoietic stem cells) [34], CD133/AC
133 (a surface marker expressed in an immature subset
of EPCs, which share more characteristics of stem/pro-
genitor cells) [35], KDR/VEGF-R2 (a typical endothelial
marker) [36], CXCR4/CD184 (a homing marker) [19]
and CD45dim (critical to exclude myeloid cells and be-
cause it has been previously demonstrated that only the
fraction of CD45dim cells harbors the “true” circulating
EPCs) [17,18]. Importantly, there are no studies in the
literature that have attempted to quantify, at the sameTable 6 Comparison of clinical outcomes after AMI between d
Nondiabetics (N = 62)
Cardiovascular mortality (%) 1.6
Stroke or TIA (%) 0
Re-infarction (%) 3.3
Unstable Angina (%) 3.3
Re-hospitalization for UA or HF (%) 8.1
MACE (%) 9.8
AMI, acute myocardial infarction; HF, heart failure; MACE, Major Adverse Cardiac Evetime, both CD45dimCD34+KDR+EPCs and the more
immature population of CD45dimCD133+KDR+ pro-
genitors in patients with AMI. Thus, until now there has
been no data available on the relation between these 2
populations in diabetics with an AMI, which would be
important to elucidate the mechanisms underlying their
impaired response. In this study, we showed for the first
time that, not only CD45dimCD34+KDR+ but also 2
the more immature precursors CD45dimCD34+CD13
3+KDR+ and CD45dimCD133+KDR+ were significantly
reduced in diabetic AMI patients by comparison with
nondiabetics. Based on these results, it is tempting to
speculate that EPCs reduction in diabetes was due, at
least in part, to impaired bone marrow mobilization.
Because, if the reduction in EPCs levels was motivated
by a decrease in survival alone it would be expected to
have reduced levels of CD45dimCD34+KDR+ but in-
creased, or at least normal, levels of the more immature
population of CD45dimCD133+KDR+ cells, due to posi-
tive feedback stimulation of bone marrow recruitment.
What we verified here was that the reduction in the
more mature EPCs population was not accompanied by
the expected up regulation of the more immature ones.
In fact, despite the reduction in CD45dimCD34+KDR+iabetics and nondiabetics







nts; TIA, transient ischemic accident; UA, unstable angina.
Figure 7 Comparison of baseline EPCs levels between patients with or without cardiovascular events during the 2-year follow-up
period. Bars represent median and error bars interquartile range of circulating EPCs numbers, quantified by flow cytometry within the first 24 h
of admission. We compared EPCs levels between patients with versus without MACE (left panel) and between patients with versus without
unstable angina (right panel), using the Mann Whitney U test.
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http://www.cardiab.com/content/13/1/101levels, CD45dimCD133+KDR+ and CD45dimCD34+CD
133+KDR+ precursors were also reduced, pointing to
impairment in recruitment mechanisms.
Besides the reduction in EPCs counts, we found that
the fraction of EPCs coexpressing the homing receptor
CXCR4 were also significantly reduced in diabetic AMI
patients what may represent an impaired homing cap-
acity of these cells to sites of vascular damage. In fact,
CXCR4, the only known receptor for SDF-1, has been
reported to play an important role in EPCs homing [19].
Moreover, CXCR4/SDF-1 interaction influences prolifer-
ation and mobilization of EPCs from the bone marrow
[37]. Since functional study of EPCs, in large popula-
tions, with in vitro assays is prohibitively expensive and
time consuming, the analysis by flow cytometry of EPCs
coexpressing CXCR4 may provide a promising alterna-
tive parameter to assess EPCs function. This is the first
study to show a reduction in numbers of EPCs coexpres-
sing CXCR4 in diabetic patients with AMI compared
with AMI nondiabetics. It is probable that this down
regulation in CXCR4+ cells denotes a homing impair-
ment, which in addition to the markedly reduction in
circulating EPCs levels may contribute to the worsened
outcome post-AMI observed in diabetics.
Pre-diabetes is a general term that refers to an inter-
mediate stage between NGM and overt DM, including
IFG and IGT. These disorders of glucose metabolism
confer an increased risk for developing both DM and
cardiovascular events [13,15,38]. In the present study
we have found that CD45dimCD34+KDR+ EPCs weresignificantly lower in pre-diabetic patients and further
reduced in those with DM, as compared with individuals
with NGM, suggesting that the reduction in the more
mature EPCs population follows the continuum of DM
development. These findings suggest that circulating
EPCs reduction is an early event in the natural history of
DM, what is in accordance to a previous work of Fadini
et al. [39]. That study has shown, in individuals from a
metabolic outpatient clinic, that circulating CD34+KDR+
cells present a progressive decline from NGM, to predia-
betics and diabetic patients and that both fasting and post-
challenge glucose were inversely related to circulating
CD34+KDR+ EPCs levels [39]. Our work further extends
these findings by the quantification of more immature
EPCs populations and the study of homing function by
the analysis of CXCR4+ subpopulations. Interestingly, we
verified that CD45dimCD133+KDR+ EPCs and both sub-
populations of CXCR4+ EPCs (CD45dimCD34+KDR+CX
CR4+ and CD45dimCD133+KDR+CXCR4+ cells) were
not significantly reduced in pre-diabetic AMI patients,
compared to patients with NGM. One possible explanation
for this divergent influence on different EPCs populations
is that pre-diabetes reduces EPCs survival (with subsequent
reduction CD45dimCD34+KDR+ EPCs levels) but, does
not impair neither bone marrow recruitment of EPCs
(leading to no differences in levels of CD45dimCD133
+KDR+ EPCs) nor homing processes (explaining the nor-
mal proportion of EPCs coexpressing CXCR4).
Previous in vitro and several animal studies have dem-
onstrated that insulin therapy has a protective role over
Figure 8 Kaplan-Meier MACE-free survival curves following an AMI, according to circulating EPCs levels presented in the acute phase.
A) Comparison of MACE-free survival curves between patients with levels of CD45dimCD34+KDR+ cells above (red line) or below (blue line) the
median. B) Comparison of MACE-free survival curves between patients with levels of CD133+KDR+ cells above (red line) or below (blue line) the
median level. The p value was determined by log-rank test.
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http://www.cardiab.com/content/13/1/101EPCs function [40-42]. More recently, Marfella et al.
have demonstrated, in hyperglycemic patients with AMI,
that EPCs levels increased after insulin infusion for in-
tensive glycemic control [29]. Regarding oral antidiabetic
drugs, several clinical studies have shown that PPAR-γ
agonists, such as rosiglitazone and pioglitazone and also
DPP-4 inhibitor sitagliptin increase EPCs levels and im-
prove their function in diabetic patients [43-45]. How-
ever, little is known about the molecular mechanisms
that regulate the beneficial effects of all these antidia-
betic drugs over EPCs.
Importantly, evidence demonstrates that the degree of
hyperglycemic control in diabetic patients is closely re-
lated to circulating EPCs levels [46,47]. However, despite
the obvious interest to know the impact of chronic anti-
diabetic therapy on EPCs response of diabetic patients
to an AMI, until now there have been no studies in
the literature addressing this subject. Therefore, in the
present work we have studied this issue and verified that,
despite the longer DM duration and the worse glycemic
control, insulin treated patients presented levels of
CD45dimCD34+KDR+ EPCs that tended to approachthat of nondiabetics. Conversely, CD45dimCD133+KD
R+ EPCs and subpopulations coexpressing the CXCR4
receptor were not ameliorated by chronic insulin ther-
apy, presenting the lowest levels in patients previously
under insulin. Regarding oral antidiabetic drugs we were
surprised to find no beneficial effect on EPCs levels,
since these results differ from some published studies
[43-45]. Notably, in accordance with the literature our
results further demonstrated that levels of both CD45
dimCD34+KDR+ and CD45dimCD133+KDR+ EPCs and
even their subpopulations coexpressing the CXCR4 sur-
face marker were inversely correlated with HbA1c,
underscoring the importance of the glycemic control for
EPCs response to an AMI. Taken together, these results
suggest that insulin, but not oral antidiabetic drugs, may
increase survival of circulating EPCs (denoted by the
trend to the normalization of CD45dimCD34+KDR+
levels). So, it is tempting to speculate that the favorable
clinical outcomes associated with glycemic control
during AMI may be partly dependent on stimulation
of EPCs-mediated neovascularization in the ischemic
myocardium. However, even chronic insulin treatment
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http://www.cardiab.com/content/13/1/101seemed unable to correct the characteristic dysfunction
of diabetics EPCs (here illustrated by the decrease in
CD45dimCD133+KDR+ EPCs, which may represent an
impairment in mobilization from bone marrow, and re-
duction in CXCR4+ subpopulations, denoting a possible
homing dysfunction). Yet, since patients under insulin
therapy had the highest HBA1c levels, it is still unknown
if with a better glycemic control chronic insulin therapy
could reverse EPCs dysfunction of diabetic patients
and completely normalize their response to an AMI.
Altogether, our results suggest that chronic hyperglycemia
and not diabetes per se, is the responsible for impaired
EPCs response of diabetic patients to myocardial ischemia.
Limitations
The limitations of our study should be acknowledged: 1)
the widespread interlaboratory variations in FACS meth-
odology used to quantify circulating EPCs is still a prob-
lem. In this study we used a standardized protocol,
which has demonstrated a high accuracy in the detection
of different EPCs subpopulations with angiogenic prop-
erties and enable us to study the differentiation and
commitment of these cells, from early precursors to
more mature circulating EPCs [17,48]. However, we
recognize that further standardization of EPCs defini-
tions and FACS protocols would be important to better
compare results between different groups; 2) the long
list of exclusion criteria limited the enrollment of higher
number of AMI patients in this study, resulting in a rela-
tively small number of patients in each antidiabetic
treatment group. Therefore, the data regarding the com-
parison of EPCs levels between the different antidiabetic
treatment categories should be interpreted with caution
because of the risk of error type II and further studies to
explore how insulin therapy may interact and affect dia-
betic EPC numbers and function in patients with AMI,
are obviously warranted; 3) since investigation of the
molecular mechanisms regulating circulating EPCs levels
in AMI diabetic patients was not under the scope of this
study, the signaling pathways underlying the observed
reduction in EPCs levels during the early phases of AMI
in diabetic as compared to nondiabetic patients are
unknown”.
Conclusions
In summary, our data demonstrates that there is a pro-
gressive decrease in EPCs response to an AMI, according
to the glycemic continuum, from NGM to pre-diabetes
and finally DM, and that the exhaustion of the EPCs pool
is influenced by the degree of glycemic control. Further-
more, it seems conceivable to use therapeutic interven-
tions, such as insulin, to try to reverse the impaired
response to an AMI of diabetics and possibly improve the
dismal prognosis of these patients.Competing interests
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